[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-open-angle-glaucoma-and-cataracts\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-open-angle-glaucoma-and-cataracts":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100645685","pei-gt-trial-for-initial-treatment-of-primary-open-angle-glaucoma-with-cataract-100645685",false,"NCT07700498","PEI-GT Trial for Initial Treatment of Primary Open-Angle Glaucoma With Cataract","Efficacy and Safety of Phacoemulsification Combined With Gonioscopy-Assisted Trabeculotomy as Initial Treatment for Primary Open-Angle Glaucoma With Cataract: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Provides written informed consent voluntarily.\n* Age 40 to 85 years.\n* Male or female.\n* Treatment-naive for glaucoma, with no prior IOP-lowering medication, glaucoma laser procedure, or glaucoma surgery.\n* Lens opacity causing decreased visual quality and clinically significant cataract.\n* Diagnosis of POAG combined with cataract by the treating ophthalmologist.\n* Best-corrected visual acuity of 0.1 or better on the Snellen chart, corresponding to LogMAR 1.0 or less.\n* Ability and willingness to complete scheduled follow-up visits and study examinations.\n\nExclusion Criteria:\n\n* Secondary glaucoma, including uveitic, pseudoexfoliative, pigmentary, steroid-induced, neovascular, traumatic, or other secondary glaucoma.\n* Angle-closure glaucoma or narrow angle inconsistent with POAG.\n* POAG without visually significant cataract.\n* Previous anti-glaucoma medication use, glaucoma surgery, or glaucoma laser treatment.\n* Advanced visual field loss, defined as visual field mean deviation worse than -12 dB.\n* Severe ocular comorbidity or inability to perform reliable visual acuity testing.\n* Known contraindication to required study medications.\n* Average RNFL thickness or GCIPL thickness less than 54 micrometers.\n* Axial length greater than 26 mm.\n* Monocular status or functional vision in only one eye.\n* Inability to complete reliable visual field or OCT testing.\n* Systemic disease that may affect ocular status or study assessment, including diabetes mellitus, uncontrolled hypertension, malignancy, renal disease, autoimmune disease, neurological disease, liver disease, cardiovascular disease, or systemic inflammatory disease.\n* Visual impairment mainly attributable to disease other than POAG or cataract.\n* Pregnancy, lactation, or planned pregnancy during the study period.","ALL","40 Years","85 Years",{"count":20,"type":21},106,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether doing phacoemulsification combined with gonioscopy-assisted trabeculotomy as an initial treatment can reduce the burden of glaucoma eye drops in adults with primary open-angle glaucoma and cataract. It will also learn whether this early surgical strategy improves ocular surface health and vision-related quality of life. The main questions it aims to answer are:\n\nDoes early combined surgery reduce the need for long-term glaucoma medications? Does early combined surgery improve ocular surface health compared with cataract surgery followed by guideline-based glaucoma eye drops? Does early combined surgery improve vision-related quality of life and anxiety compared with the medication-based treatment strategy? What medical problems or complications do participants have after treatment? Researchers will compare phacoemulsification combined with gonioscopy-assisted trabeculotomy to phacoemulsification followed by guideline-based topical eye pressure-lowering medications.\n\nParticipants will:\n\nUndergo cataract surgery with or without gonioscopy-assisted trabeculotomy Attend follow-up visits for 24 months after treatment Have eye pressure, visual acuity, OCT, AS-OCT, visual field, ocular surface, and safety examinations at scheduled visits Complete quality-of-life and anxiety questionnaires at scheduled visits Provide tear samples at selected visits for biomarker testing where applicable",[27],"Primary Open Angle Glaucoma and Cataracts","RECRUITING","2026-07-07",{"date":31,"type":32},"2026-07-14","ACTUAL",{"date":34,"type":21},"2026-07-15",{"date":36,"type":21},"2030-12-31",{"name":38,"class":39},"Nanfang Hospital, Southern Medical University","OTHER",5]